Open-mkt buys · 90d
—
0 trades · 0 insiders
Open-mkt sales · 90d
—
0 trades · 0 insiders
Net · 90d
$0
Insiders on file
46
Daily buy vs sell · 90 days
No data yet.
Insiders
| Insider | Role | Trades | Bought | Sold | Last trade |
|---|---|---|---|---|---|
| LaSpaluto Michelle | Chief Financial Officer | 23 | $0 | $16.4K | 2025-04-21 |
| Vakiener Victoria | Director | 10 | $0 | $0 | 2025-04-21 |
| Melemed Allen S. | Chief Medical Officer | 17 | $0 | $13.8K | 2025-04-21 |
| Decker Lisa Lynn | Director | 4 | $0 | $0 | 2025-04-21 |
| Jakeman David | VP of Finance and Accounting | 46 | $0 | $134.4K | 2025-04-21 |
| Meyer Robert J. | Director | 23 | $74.2K | $0 | 2025-04-21 |
| Riga Thomas J | COO and CCO | 6 | $0 | $0 | 2025-04-21 |
| Andriole Michael T. | President and CEO | 32 | $288.2K | $45.8K | 2025-04-21 |
| Multani Pratik S | Director | 12 | $0 | $0 | 2025-04-21 |
| Sherman Michael A. | Chief Executive Officer | 24 | $307.8K | $0 | 2025-04-21 |
| Alrutz Michael Albert | SVP AND GENERAL COUNSEL | 20 | $0 | $7.2K | 2025-04-21 |
| MIDDLETON FRED A | Director | 34 | $464.4K | $0 | 2025-04-21 |
| KOZIN MARC D | Director | 4 | $0 | $0 | 2025-04-21 |
| DEMSKI MARTHA J | Director | 87 | $149.8K | $931.1K | 2025-04-21 |
| Gilliss Catherine | Director | 11 | $0 | $0 | 2023-06-09 |
| Machado Patrick | Director | 12 | $70.8K | $0 | 2023-06-09 |
| CANTEX PHARMACEUTICALS, INC. | 10% Owner | 1 | $0 | $37.38M | 2021-09-14 |
| Greissing Ed | Director | 4 | $0 | $0 | 2020-06-11 |
| Nichols Garrett | Chief Medical Officer | 22 | $0 | $85.1K | 2020-02-10 |
| Daly James M | Director | 7 | $0 | $0 | 2019-06-20 |
| Renaud Ronald C JR | Director | 6 | $0 | $0 | 2019-06-20 |
| Trost Timothy W. | Sr. Vice President and CFO | 65 | $0 | $2.79M | 2019-05-22 |
| Berrey M Michelle | See Remarks | 44 | $497.5K | $0 | 2019-01-23 |
| MARIO ERNEST | Director | 106 | $2.59M | $1.22M | 2018-05-18 |
| Richardson Linda M | Chief Commerical Officer | 11 | $0 | $88.7K | 2018-05-14 |
| LEONARD JOHN M. | Director | 8 | $163.4K | $25.1K | 2017-06-28 |
| NIEDEL JAMES | Director, 10% Owner | 18 | $0 | $41.41M | 2017-06-28 |
| Ricciardi Lisa | Director | 5 | $75.2K | $0 | 2016-06-24 |
| WOLLAEGER TIMOTHY | Director, 10% Owner | 35 | $46.1K | $6.05M | 2016-03-01 |
| Rogers Michael D. | Chief Development Officer | 7 | $0 | $0 | 2016-01-08 |
| Sanderling Venture Partners V, LP | 10% Owner | 23 | $0 | $3.60M | 2014-09-12 |
| Sanderling Venture Partners VI Co Investment Fund LP | 10% Owner | 2 | $0 | $2.45M | 2014-09-08 |
| DRAKE RODMAN L | Director | 10 | $52.7K | $0 | 2014-06-20 |
| Canaan Partners VII LLC | Director | 2 | $0 | $0 | 2014-03-26 |
| Ratcliffe Liam | 10% Owner | 1 | $0 | $0 | 2014-03-18 |
| MOCH KENNETH I | President and CEO | 13 | $0 | $753.5K | 2014-03-13 |
| Canaan VII L P | Director, 10% Owner | 11 | $0 | $10.47M | 2014-01-21 |
| SANDERLING V BETEILIGUNGS GMBH & CO KG | 10% Owner | 2 | $0 | $0 | 2013-11-13 |
| New Leaf Ventures II, L.P. | 10% Owner | 3 | $0 | $9.08M | 2013-10-23 |
| Hutton Wende S | Director, 10% Owner | 11 | $0 | $10.47M | 2013-10-23 |
| CHAMPSI FARAH | Director | 7 | $0 | $6.94M | 2013-10-23 |
| PAPPAS ARTHUR M | Director | 3 | $0 | $3.36M | 2013-10-23 |
| A.M. Pappas Life Science Ventures IV LP | Other | 2 | $0 | $0 | 2013-04-16 |
| Sanderling Ventures Management VI | 10% Owner | 1 | $0 | $0 | 2013-04-16 |
| Sanderling VI Limited Partnership | 10% Owner | 14 | $0 | $0 | 2013-04-16 |
| ALTA EMBARCADERO BIOPHARMA PARTNERS III LLC | Other | 6 | $0 | $0 | 2013-04-16 |
Trade history
| Insider | Role | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|---|
| Alrutz Michael Albert | SVP AND GENERAL COUNSEL | D To issuer deriv | 2025-04-21 | 2025-04-21 | 15,000 | — | $0 | 0 | SEC↗ |
| Alrutz Michael Albert | SVP AND GENERAL COUNSEL | D To issuer deriv | 2025-04-21 | 2025-04-21 | 135,000 | — | $0 | 0 | SEC↗ |
| Alrutz Michael Albert | SVP AND GENERAL COUNSEL | D To issuer deriv | 2025-04-21 | 2025-04-21 | 45,750 | — | $0 | 0 | SEC↗ |
| Alrutz Michael Albert | SVP AND GENERAL COUNSEL | D To issuer deriv | 2025-04-21 | 2025-04-21 | 178,000 | — | $0 | 0 | SEC↗ |
| Alrutz Michael Albert | SVP AND GENERAL COUNSEL | D To issuer deriv | 2025-04-21 | 2025-04-21 | 176,000 | — | $0 | 0 | SEC↗ |
| Alrutz Michael Albert | SVP AND GENERAL COUNSEL | D To issuer deriv | 2025-04-21 | 2025-04-21 | 165,000 | — | $0 | 0 | SEC↗ |
| Alrutz Michael Albert | SVP AND GENERAL COUNSEL | D To issuer deriv | 2025-04-21 | 2025-04-21 | 170,000 | — | $0 | 0 | SEC↗ |
| Alrutz Michael Albert | SVP AND GENERAL COUNSEL | D To issuer deriv | 2025-04-21 | 2025-04-21 | 200,000 | — | $0 | 0 | SEC↗ |
| Alrutz Michael Albert | SVP AND GENERAL COUNSEL | D To issuer deriv | 2025-04-21 | 2025-04-21 | 128,550 | — | $0 | 0 | SEC↗ |
| Alrutz Michael Albert | SVP AND GENERAL COUNSEL | D To issuer deriv | 2025-04-21 | 2025-04-21 | 131,250 | — | $0 | 0 | SEC↗ |
| Alrutz Michael Albert | SVP AND GENERAL COUNSEL | D To issuer deriv | 2025-04-21 | 2025-04-21 | 250,000 | — | $0 | 0 | SEC↗ |
| Andriole Michael T. | PRESIDENT AND CEO | D To issuer deriv | 2025-04-21 | 2025-04-21 | 150,000 | — | $0 | 0 | SEC↗ |
| Andriole Michael T. | PRESIDENT AND CEO | D To issuer deriv | 2025-04-21 | 2025-04-21 | 900,000 | — | $0 | 0 | SEC↗ |
| Andriole Michael T. | PRESIDENT AND CEO | D To issuer deriv | 2025-04-21 | 2025-04-21 | 502,500 | — | $0 | 0 | SEC↗ |
| Andriole Michael T. | PRESIDENT AND CEO | D To issuer deriv | 2025-04-21 | 2025-04-21 | 192,500 | — | $0 | 0 | SEC↗ |
| Andriole Michael T. | PRESIDENT AND CEO | D To issuer deriv | 2025-04-21 | 2025-04-21 | 250,000 | — | $0 | 0 | SEC↗ |
| Andriole Michael T. | PRESIDENT AND CEO | D To issuer deriv | 2025-04-21 | 2025-04-21 | 300,000 | — | $0 | 0 | SEC↗ |
| Andriole Michael T. | PRESIDENT AND CEO | D To issuer deriv | 2025-04-21 | 2025-04-21 | 192,825 | — | $0 | 0 | SEC↗ |
| Andriole Michael T. | PRESIDENT AND CEO | D To issuer deriv | 2025-04-21 | 2025-04-21 | 450,000 | — | $0 | 0 | SEC↗ |
| Decker Lisa Lynn | Director | D To issuer deriv | 2025-04-21 | 2025-04-21 | 100,000 | — | $0 | 0 | SEC↗ |
| Decker Lisa Lynn | Director | D To issuer deriv | 2025-04-21 | 2025-04-21 | 60,000 | — | $0 | 0 | SEC↗ |
| DEMSKI MARTHA J | Director | D To issuer deriv | 2025-04-21 | 2025-04-21 | 9,000 | — | $0 | 0 | SEC↗ |
| DEMSKI MARTHA J | Director | D To issuer deriv | 2025-04-21 | 2025-04-21 | 21,000 | — | $0 | 0 | SEC↗ |
| DEMSKI MARTHA J | Director | D To issuer deriv | 2025-04-21 | 2025-04-21 | 60,000 | — | $0 | 0 | SEC↗ |
| DEMSKI MARTHA J | Director | D To issuer deriv | 2025-04-21 | 2025-04-21 | 60,000 | — | $0 | 0 | SEC↗ |
| DEMSKI MARTHA J | Director | D To issuer deriv | 2025-04-21 | 2025-04-21 | 50,000 | — | $0 | 0 | SEC↗ |
| DEMSKI MARTHA J | Director | D To issuer deriv | 2025-04-21 | 2025-04-21 | 35,000 | — | $0 | 0 | SEC↗ |
| DEMSKI MARTHA J | Director | D To issuer deriv | 2025-04-21 | 2025-04-21 | 35,000 | — | $0 | 0 | SEC↗ |
| DEMSKI MARTHA J | Director | D To issuer deriv | 2025-04-21 | 2025-04-21 | 21,000 | — | $0 | 0 | SEC↗ |
| DEMSKI MARTHA J | Director | D To issuer deriv | 2025-04-21 | 2025-04-21 | 9,000 | — | $0 | 0 | SEC↗ |
| DEMSKI MARTHA J | Director | D To issuer deriv | 2025-04-21 | 2025-04-21 | 21,000 | — | $0 | 0 | SEC↗ |
| Jakeman David | VP OF FINANCE AND ACCOUNTING | D To issuer deriv | 2025-04-21 | 2025-04-21 | 29,900 | — | $0 | 0 | SEC↗ |
| Jakeman David | VP OF FINANCE AND ACCOUNTING | D To issuer deriv | 2025-04-21 | 2025-04-21 | 30,000 | — | $0 | 0 | SEC↗ |
| Jakeman David | VP OF FINANCE AND ACCOUNTING | D To issuer deriv | 2025-04-21 | 2025-04-21 | 1,500 | — | $0 | 0 | SEC↗ |
| Jakeman David | VP OF FINANCE AND ACCOUNTING | D To issuer deriv | 2025-04-21 | 2025-04-21 | 28,320 | — | $0 | 0 | SEC↗ |
| Jakeman David | VP OF FINANCE AND ACCOUNTING | D To issuer deriv | 2025-04-21 | 2025-04-21 | 10,000 | — | $0 | 0 | SEC↗ |
| Jakeman David | VP OF FINANCE AND ACCOUNTING | D To issuer deriv | 2025-04-21 | 2025-04-21 | 9,360 | — | $0 | 0 | SEC↗ |
| Jakeman David | VP OF FINANCE AND ACCOUNTING | D To issuer deriv | 2025-04-21 | 2025-04-21 | 1,250 | — | $0 | 0 | SEC↗ |
| Jakeman David | VP OF FINANCE AND ACCOUNTING | D To issuer deriv | 2025-04-21 | 2025-04-21 | 7,200 | — | $0 | 0 | SEC↗ |
| Jakeman David | VP OF FINANCE AND ACCOUNTING | D To issuer deriv | 2025-04-21 | 2025-04-21 | 10,000 | — | $0 | 0 | SEC↗ |
| Jakeman David | VP OF FINANCE AND ACCOUNTING | D To issuer deriv | 2025-04-21 | 2025-04-21 | 10,150 | — | $0 | 0 | SEC↗ |
| Jakeman David | VP OF FINANCE AND ACCOUNTING | D To issuer deriv | 2025-04-21 | 2025-04-21 | 65,000 | — | $0 | 0 | SEC↗ |
| Jakeman David | VP OF FINANCE AND ACCOUNTING | D To issuer deriv | 2025-04-21 | 2025-04-21 | 64,500 | — | $0 | 0 | SEC↗ |
| Jakeman David | VP OF FINANCE AND ACCOUNTING | D To issuer deriv | 2025-04-21 | 2025-04-21 | 18,000 | — | $0 | 0 | SEC↗ |
| Jakeman David | VP OF FINANCE AND ACCOUNTING | D To issuer deriv | 2025-04-21 | 2025-04-21 | 24,950 | — | $0 | 0 | SEC↗ |
| Jakeman David | VP OF FINANCE AND ACCOUNTING | D To issuer deriv | 2025-04-21 | 2025-04-21 | 1,500 | — | $0 | 0 | SEC↗ |
| KOZIN MARC D | Director | D To issuer deriv | 2025-04-21 | 2025-04-21 | 100,000 | — | $0 | 0 | SEC↗ |
| KOZIN MARC D | Director | D To issuer deriv | 2025-04-21 | 2025-04-21 | 60,000 | — | $0 | 0 | SEC↗ |
| LaSpaluto Michelle | CHIEF FINANCIAL OFFICER | D To issuer deriv | 2025-04-21 | 2025-04-21 | 64,275 | — | $0 | 0 | SEC↗ |
| LaSpaluto Michelle | CHIEF FINANCIAL OFFICER | D To issuer deriv | 2025-04-21 | 2025-04-21 | 95,000 | — | $0 | 0 | SEC↗ |
| LaSpaluto Michelle | CHIEF FINANCIAL OFFICER | D To issuer deriv | 2025-04-21 | 2025-04-21 | 90,000 | — | $0 | 0 | SEC↗ |
| LaSpaluto Michelle | CHIEF FINANCIAL OFFICER | D To issuer deriv | 2025-04-21 | 2025-04-21 | 62,067 | — | $0 | 0 | SEC↗ |
| LaSpaluto Michelle | CHIEF FINANCIAL OFFICER | D To issuer deriv | 2025-04-21 | 2025-04-21 | 48,438 | — | $0 | 0 | SEC↗ |
| LaSpaluto Michelle | CHIEF FINANCIAL OFFICER | D To issuer deriv | 2025-04-21 | 2025-04-21 | 250,000 | — | $0 | 0 | SEC↗ |
| LaSpaluto Michelle | CHIEF FINANCIAL OFFICER | D To issuer deriv | 2025-04-21 | 2025-04-21 | 13,000 | — | $0 | 0 | SEC↗ |
| LaSpaluto Michelle | CHIEF FINANCIAL OFFICER | D To issuer deriv | 2025-04-21 | 2025-04-21 | 1,250 | — | $0 | 0 | SEC↗ |
| LaSpaluto Michelle | CHIEF FINANCIAL OFFICER | D To issuer deriv | 2025-04-21 | 2025-04-21 | 15,000 | — | $0 | 0 | SEC↗ |
| LaSpaluto Michelle | CHIEF FINANCIAL OFFICER | D To issuer deriv | 2025-04-21 | 2025-04-21 | 1,500 | — | $0 | 0 | SEC↗ |
| LaSpaluto Michelle | CHIEF FINANCIAL OFFICER | D To issuer deriv | 2025-04-21 | 2025-04-21 | 18,700 | — | $0 | 0 | SEC↗ |
| LaSpaluto Michelle | CHIEF FINANCIAL OFFICER | D To issuer deriv | 2025-04-21 | 2025-04-21 | 17,000 | — | $0 | 0 | SEC↗ |
| LaSpaluto Michelle | CHIEF FINANCIAL OFFICER | D To issuer deriv | 2025-04-21 | 2025-04-21 | 150,000 | — | $0 | 0 | SEC↗ |
| LaSpaluto Michelle | CHIEF FINANCIAL OFFICER | D To issuer deriv | 2025-04-21 | 2025-04-21 | 8,098 | — | $0 | 0 | SEC↗ |
| Melemed Allen S. | CHIEF MEDICAL OFFICER | D To issuer deriv | 2025-04-21 | 2025-04-21 | 240,000 | — | $0 | 0 | SEC↗ |
| Melemed Allen S. | CHIEF MEDICAL OFFICER | D To issuer deriv | 2025-04-21 | 2025-04-21 | 168,750 | — | $0 | 0 | SEC↗ |
| Melemed Allen S. | CHIEF MEDICAL OFFICER | D To issuer deriv | 2025-04-21 | 2025-04-21 | 154,260 | — | $0 | 0 | SEC↗ |
| Melemed Allen S. | CHIEF MEDICAL OFFICER | D To issuer deriv | 2025-04-21 | 2025-04-21 | 275,000 | — | $0 | 0 | SEC↗ |
| Melemed Allen S. | CHIEF MEDICAL OFFICER | D To issuer deriv | 2025-04-21 | 2025-04-21 | 190,000 | — | $0 | 0 | SEC↗ |
| Melemed Allen S. | CHIEF MEDICAL OFFICER | D To issuer deriv | 2025-04-21 | 2025-04-21 | 400,000 | — | $0 | 0 | SEC↗ |
| Meyer Robert J. | Director | D To issuer deriv | 2025-04-21 | 2025-04-21 | 35,000 | — | $0 | 0 | SEC↗ |
| Meyer Robert J. | Director | D To issuer deriv | 2025-04-21 | 2025-04-21 | 60,000 | — | $0 | 0 | SEC↗ |
| Meyer Robert J. | Director | D To issuer deriv | 2025-04-21 | 2025-04-21 | 50,000 | — | $0 | 0 | SEC↗ |
| Meyer Robert J. | Director | D To issuer deriv | 2025-04-21 | 2025-04-21 | 35,000 | — | $0 | 0 | SEC↗ |
| Meyer Robert J. | Director | D To issuer deriv | 2025-04-21 | 2025-04-21 | 60,000 | — | $0 | 0 | SEC↗ |
| Meyer Robert J. | Director | D To issuer deriv | 2025-04-21 | 2025-04-21 | 21,000 | — | $0 | 0 | SEC↗ |
| Meyer Robert J. | Director | D To issuer deriv | 2025-04-21 | 2025-04-21 | 21,000 | — | $0 | 0 | SEC↗ |
| Meyer Robert J. | Director | D To issuer deriv | 2025-04-21 | 2025-04-21 | 42,000 | — | $0 | 0 | SEC↗ |
| MIDDLETON FRED A | Director | D To issuer deriv | 2025-04-21 | 2025-04-21 | 35,000 | — | $0 | 0 | SEC↗ |
| MIDDLETON FRED A | Director | D To issuer deriv | 2025-04-21 | 2025-04-21 | 60,000 | — | $0 | 0 | SEC↗ |
| MIDDLETON FRED A | Director | D To issuer deriv | 2025-04-21 | 2025-04-21 | 50,000 | — | $0 | 0 | SEC↗ |
| MIDDLETON FRED A | Director | D To issuer deriv | 2025-04-21 | 2025-04-21 | 35,000 | — | $0 | 0 | SEC↗ |
| MIDDLETON FRED A | Director | D To issuer deriv | 2025-04-21 | 2025-04-21 | 60,000 | — | $0 | 0 | SEC↗ |
| MIDDLETON FRED A | Director | D To issuer deriv | 2025-04-21 | 2025-04-21 | 21,000 | — | $0 | 0 | SEC↗ |
| MIDDLETON FRED A | Director | D To issuer deriv | 2025-04-21 | 2025-04-21 | 21,000 | — | $0 | 0 | SEC↗ |
| MIDDLETON FRED A | Director | D To issuer deriv | 2025-04-21 | 2025-04-21 | 42,000 | — | $0 | 0 | SEC↗ |
| Multani Pratik S | Director | D To issuer deriv | 2025-04-21 | 2025-04-21 | 50,000 | — | $0 | 0 | SEC↗ |
| Multani Pratik S | Director | D To issuer deriv | 2025-04-21 | 2025-04-21 | 60,000 | — | $0 | 0 | SEC↗ |
| Multani Pratik S | Director | D To issuer deriv | 2025-04-21 | 2025-04-21 | 35,000 | — | $0 | 0 | SEC↗ |
| Multani Pratik S | Director | D To issuer deriv | 2025-04-21 | 2025-04-21 | 60,000 | — | $0 | 0 | SEC↗ |
| Multani Pratik S | Director | D To issuer deriv | 2025-04-21 | 2025-04-21 | 60,000 | — | $0 | 0 | SEC↗ |
| Multani Pratik S | Director | D To issuer deriv | 2025-04-21 | 2025-04-21 | 35,000 | — | $0 | 0 | SEC↗ |
| Riga Thomas J | COO and CCO | D To issuer deriv | 2025-04-21 | 2025-04-21 | 325,000 | — | $0 | 0 | SEC↗ |
| Riga Thomas J | COO and CCO | D To issuer deriv | 2025-04-21 | 2025-04-21 | 800,000 | — | $0 | 0 | SEC↗ |
| Sherman Michael A. | Chief Executive Officer | D To issuer deriv | 2025-04-21 | 2025-04-21 | 700,000 | — | $0 | 0 | SEC↗ |
| Sherman Michael A. | Chief Executive Officer | D To issuer deriv | 2025-04-21 | 2025-04-21 | 632,500 | — | $0 | 0 | SEC↗ |
| Sherman Michael A. | Chief Executive Officer | D To issuer deriv | 2025-04-21 | 2025-04-21 | 875,000 | — | $0 | 0 | SEC↗ |
| Sherman Michael A. | Chief Executive Officer | D To issuer deriv | 2025-04-21 | 2025-04-21 | 60,000 | — | $0 | 0 | SEC↗ |
| Sherman Michael A. | Chief Executive Officer | D To issuer deriv | 2025-04-21 | 2025-04-21 | 557,050 | — | $0 | 0 | SEC↗ |
| Sherman Michael A. | Chief Executive Officer | D To issuer deriv | 2025-04-21 | 2025-04-21 | 1,150,000 | — | $0 | 0 | SEC↗ |
| Vakiener Victoria | Director | D To issuer deriv | 2025-04-21 | 2025-04-21 | 50,000 | — | $0 | 0 | SEC↗ |
| Vakiener Victoria | Director | D To issuer deriv | 2025-04-21 | 2025-04-21 | 60,000 | — | $0 | 0 | SEC↗ |
| Vakiener Victoria | Director | D To issuer deriv | 2025-04-21 | 2025-04-21 | 60,000 | — | $0 | 0 | SEC↗ |
| Vakiener Victoria | Director | D To issuer deriv | 2025-04-21 | 2025-04-21 | 35,000 | — | $0 | 0 | SEC↗ |
| Vakiener Victoria | Director | D To issuer deriv | 2025-04-21 | 2025-04-21 | 60,000 | — | $0 | 0 | SEC↗ |
| Alrutz Michael Albert | SVP AND GENERAL COUNSEL | D To issuer | 2025-04-21 | 2025-04-21 | 216,689 | $8.55 | $1.85M | 0 | SEC↗ |
| Andriole Michael T. | PRESIDENT AND CEO | D To issuer | 2025-04-21 | 2025-04-21 | 630,828 | $8.55 | $5.39M | 0 | SEC↗ |
| DEMSKI MARTHA J | Director | D To issuer | 2025-04-21 | 2025-04-21 | 72,055 | $8.55 | $616.1K | 0 | SEC↗ |
| Jakeman David | VP OF FINANCE AND ACCOUNTING | D To issuer | 2025-04-21 | 2025-04-21 | 156,209 | $8.55 | $1.34M | 0 | SEC↗ |
| LaSpaluto Michelle | CHIEF FINANCIAL OFFICER | D To issuer | 2025-04-21 | 2025-04-21 | 181,541 | $8.55 | $1.55M | 0 | SEC↗ |
| Melemed Allen S. | CHIEF MEDICAL OFFICER | D To issuer | 2025-04-21 | 2025-04-21 | 173,852 | $8.55 | $1.49M | 0 | SEC↗ |
| Meyer Robert J. | Director | D To issuer | 2025-04-21 | 2025-04-21 | 35,150 | $8.55 | $300.5K | 0 | SEC↗ |
| MIDDLETON FRED A | Director | D To issuer | 2025-04-21 | 2025-04-21 | 40,000 | $8.55 | $342.0K | 0 | SEC↗ |
| MIDDLETON FRED A | Director | D To issuer | 2025-04-21 | 2025-04-21 | 2,776,093 | $8.55 | $23.74M | 0 | SEC↗ |
| MIDDLETON FRED A | Director | D To issuer | 2025-04-21 | 2025-04-21 | 531,861 | $8.55 | $4.55M | 0 | SEC↗ |
| MIDDLETON FRED A | Director | D To issuer | 2025-04-21 | 2025-04-21 | 207,523 | $8.55 | $1.77M | 0 | SEC↗ |
| MIDDLETON FRED A | Director | D To issuer | 2025-04-21 | 2025-04-21 | 60,000 | $8.55 | $513.0K | 0 | SEC↗ |
| Riga Thomas J | COO and CCO | D To issuer | 2025-04-21 | 2025-04-21 | 60,828 | $8.55 | $520.1K | 0 | SEC↗ |
| Sherman Michael A. | Chief Executive Officer | D To issuer | 2025-04-21 | 2025-04-21 | 102,995 | $8.55 | $880.6K | 0 | SEC↗ |
| Sherman Michael A. | Chief Executive Officer | D To issuer | 2025-04-21 | 2025-04-21 | 87,000 | $8.55 | $743.9K | 0 | SEC↗ |
| Sherman Michael A. | Chief Executive Officer | D To issuer | 2025-04-21 | 2025-04-21 | 233,413 | $8.55 | $2.00M | 0 | SEC↗ |
| LaSpaluto Michelle | CHIEF FINANCIAL OFFICER | S Sale | 2025-02-13 | 2025-02-14 | 2,260 | $4.51 | $10.2K | 172,977 | SEC↗ |
| Jakeman David | VP OF FINANCE AND ACCOUNTING | S Sale | 2025-02-13 | 2025-02-14 | 300 | $4.53 | $1.4K | 148,987 | SEC↗ |
| Alrutz Michael Albert | SVP AND GENERAL COUNSEL | S Sale | 2025-02-13 | 2025-02-14 | 1,600 | $4.52 | $7.2K | 213,596 | SEC↗ |
| Andriole Michael T. | PRESIDENT AND CEO | S Sale | 2025-02-13 | 2025-02-14 | 7,370 | $4.52 | $33.3K | 609,603 | SEC↗ |
| Melemed Allen S. | CHIEF MEDICAL OFFICER | S Sale | 2025-02-13 | 2025-02-14 | 3,065 | $4.50 | $13.8K | 152,875 | SEC↗ |
| Andriole Michael T. | PRESIDENT AND CEO | S Sale | 2025-01-30 | 2025-01-31 | 2,350 | $4.10 | $9.6K | 616,973 | SEC↗ |
| LaSpaluto Michelle | CHIEF FINANCIAL OFFICER | S Sale | 2025-01-30 | 2025-01-31 | 1,015 | $4.11 | $4.2K | 175,237 | SEC↗ |
| Jakeman David | VP OF FINANCE AND ACCOUNTING | S Sale | 2025-01-30 | 2025-01-31 | 2,800 | $4.10 | $11.5K | 149,287 | SEC↗ |
| Andriole Michael T. | PRESIDENT AND CEO | A Award deriv | 2025-01-07 | 2025-01-10 | 900,000 | — | $0 | 900,000 | SEC↗ |
| Alrutz Michael Albert | SVP AND GENERAL COUNSEL | A Award deriv | 2025-01-07 | 2025-01-10 | 250,000 | — | $0 | 250,000 | SEC↗ |
| Riga Thomas J | COO and CCO | A Award deriv | 2025-01-07 | 2025-01-10 | 325,000 | — | $0 | 325,000 | SEC↗ |
| Jakeman David | VP OF FINANCE AND ACCOUNTING | A Award deriv | 2025-01-07 | 2025-01-10 | 65,000 | — | $0 | 65,000 | SEC↗ |
| Melemed Allen S. | CHIEF MEDICAL OFFICER | A Award deriv | 2025-01-07 | 2025-01-10 | 275,000 | — | $0 | 275,000 | SEC↗ |
| LaSpaluto Michelle | CHIEF FINANCIAL OFFICER | A Award deriv | 2025-01-07 | 2025-01-10 | 250,000 | — | $0 | 250,000 | SEC↗ |
| Andriole Michael T. | PRESIDENT AND CEO | A Award | 2025-01-07 | 2025-01-10 | 150,000 | — | $0 | 619,323 | SEC↗ |
| Alrutz Michael Albert | SVP AND GENERAL COUNSEL | A Award | 2025-01-07 | 2025-01-10 | 41,667 | — | $0 | 215,196 | SEC↗ |
| Riga Thomas J | COO and CCO | A Award | 2025-01-07 | 2025-01-10 | 54,275 | — | $0 | 57,501 | SEC↗ |
| Jakeman David | VP OF FINANCE AND ACCOUNTING | A Award | 2025-01-07 | 2025-01-10 | 10,855 | — | $0 | 152,087 | SEC↗ |
| Melemed Allen S. | CHIEF MEDICAL OFFICER | A Award | 2025-01-07 | 2025-01-10 | 45,925 | — | $0 | 155,940 | SEC↗ |
| LaSpaluto Michelle | CHIEF FINANCIAL OFFICER | A Award | 2025-01-07 | 2025-01-10 | 41,667 | — | $0 | 176,252 | SEC↗ |
| MIDDLETON FRED A | Director | G Gift | 2024-10-28 | 2024-10-30 | 60,000 | — | $0 | 40,000 | SEC↗ |
| Andriole Michael T. | PRESIDENT AND CEO | S Sale | 2024-08-08 | 2024-08-09 | 1,285 | $0.83 | $1.1K | 462,453 | SEC↗ |
| Sherman Michael A. | Chief Executive Officer | A Award deriv | 2024-06-20 | 2024-06-21 | 60,000 | — | $0 | 60,000 | SEC↗ |
| DEMSKI MARTHA J | Director | A Award deriv | 2024-06-20 | 2024-06-21 | 60,000 | — | $0 | 60,000 | SEC↗ |
| Decker Lisa Lynn | Director | A Award deriv | 2024-06-20 | 2024-06-21 | 60,000 | — | $0 | 60,000 | SEC↗ |
| KOZIN MARC D | Director | A Award deriv | 2024-06-20 | 2024-06-21 | 60,000 | — | $0 | 60,000 | SEC↗ |
| Meyer Robert J. | Director | A Award deriv | 2024-06-20 | 2024-06-21 | 60,000 | — | $0 | 60,000 | SEC↗ |
| MIDDLETON FRED A | Director | A Award deriv | 2024-06-20 | 2024-06-21 | 60,000 | — | $0 | 60,000 | SEC↗ |
| Multani Pratik S | Director | A Award deriv | 2024-06-20 | 2024-06-21 | 60,000 | — | $0 | 60,000 | SEC↗ |
| Vakiener Victoria | Director | A Award deriv | 2024-06-20 | 2024-06-21 | 60,000 | — | $0 | 60,000 | SEC↗ |
| KOZIN MARC D | Director | A Award deriv | 2024-03-20 | 2024-03-21 | 100,000 | — | $0 | 100,000 | SEC↗ |
| Jakeman David | VP OF FINANCE AND ACCOUNTING | S Sale | 2024-02-14 | 2024-02-16 | 2,660 | $1.04 | $2.8K | 141,232 | SEC↗ |
| LaSpaluto Michelle | CHIEF FINANCIAL OFFICER | S Sale | 2024-02-14 | 2024-02-16 | 1,940 | $1.04 | $2.0K | 110,999 | SEC↗ |
| Andriole Michael T. | PRESIDENT AND CEO | S Sale | 2024-02-14 | 2024-02-16 | 1,744 | $1.04 | $1.8K | 447,021 | SEC↗ |
| Andriole Michael T. | PRESIDENT AND CEO | A Award deriv | 2024-02-01 | 2024-02-02 | 502,500 | — | $0 | 502,500 | SEC↗ |
| Jakeman David | VP OF FINANCE AND ACCOUNTING | A Award deriv | 2024-02-01 | 2024-02-02 | 64,500 | — | $0 | 64,500 | SEC↗ |
| Melemed Allen S. | CHIEF MEDICAL OFFICER | A Award deriv | 2024-02-01 | 2024-02-02 | 168,750 | — | $0 | 168,750 | SEC↗ |
| Alrutz Michael Albert | SVP AND GENERAL COUNSEL | A Award deriv | 2024-02-01 | 2024-02-02 | 131,250 | — | $0 | 131,250 | SEC↗ |
| LaSpaluto Michelle | CHIEF FINANCIAL OFFICER | A Award deriv | 2024-02-01 | 2024-02-02 | 150,000 | — | $0 | 150,000 | SEC↗ |
| Andriole Michael T. | PRESIDENT AND CEO | A Award | 2024-02-01 | 2024-02-02 | 83,750 | — | $0 | 448,765 | SEC↗ |
| Jakeman David | VP OF FINANCE AND ACCOUNTING | A Award | 2024-02-01 | 2024-02-02 | 10,750 | — | $0 | 143,892 | SEC↗ |
| Melemed Allen S. | CHIEF MEDICAL OFFICER | A Award | 2024-02-01 | 2024-02-02 | 28,125 | — | $0 | 86,430 | SEC↗ |
| Alrutz Michael Albert | SVP AND GENERAL COUNSEL | A Award | 2024-02-01 | 2024-02-02 | 21,875 | — | $0 | 168,098 | SEC↗ |
| LaSpaluto Michelle | CHIEF FINANCIAL OFFICER | A Award | 2024-02-01 | 2024-02-02 | 25,000 | — | $0 | 112,939 | SEC↗ |
| Andriole Michael T. | President and CEO | G Gift | 2023-12-29 | 2023-12-29 | 17,000 | — | $0 | 365,015 | SEC↗ |
| Decker Lisa Lynn | Director | A Award deriv | 2023-12-28 | 2024-01-02 | 100,000 | — | $0 | 100,000 | SEC↗ |
| LaSpaluto Michelle | Chief Financial Officer | A Award deriv | 2023-12-01 | 2023-12-04 | 17,000 | — | $0 | 17,000 | SEC↗ |
| MIDDLETON FRED A | Director | P Buy | 2023-11-17 | 2023-11-20 | 17,295 | $0.96 | $16.6K | 100,000 | SEC↗ |
| Riga Thomas J | COO and CCO | A Award deriv | 2023-11-16 | 2023-11-16 | 800,000 | — | $0 | 800,000 | SEC↗ |
| MIDDLETON FRED A | Director | P Buy | 2023-11-10 | 2023-11-13 | 2,705 | $0.92 | $2.5K | 82,705 | SEC↗ |
| Jakeman David | VP of Finance and Accounting | S Sale | 2023-09-28 | 2023-09-28 | 3,610 | $0.99 | $3.6K | 133,142 | SEC↗ |
| MIDDLETON FRED A | Director | P Buy | 2023-09-25 | 2023-09-26 | 20,000 | $0.98 | $19.6K | 80,000 | SEC↗ |
| Jakeman David | VP of Finance and Accounting | A Award deriv | 2023-09-20 | 2023-09-20 | 18,000 | — | $0 | 18,000 | SEC↗ |
| Andriole Michael T. | President and CEO | A Award deriv | 2023-08-01 | 2023-08-01 | 150,000 | — | $0 | 150,000 | SEC↗ |
| Andriole Michael T. | President and CEO | A Award | 2023-08-01 | 2023-08-01 | 25,000 | $1.19 | $29.8K | 382,015 | SEC↗ |
| Vakiener Victoria | Director | A Award deriv | 2023-06-09 | 2023-06-12 | 60,000 | — | $0 | 60,000 | SEC↗ |
| DEMSKI MARTHA J | Director | A Award deriv | 2023-06-09 | 2023-06-12 | 60,000 | — | $0 | 60,000 | SEC↗ |
| Gilliss Catherine | Director | A Award deriv | 2023-06-09 | 2023-06-12 | 60,000 | — | $0 | 60,000 | SEC↗ |
| Machado Patrick | Director | A Award deriv | 2023-06-09 | 2023-06-12 | 60,000 | — | $0 | 60,000 | SEC↗ |
| Meyer Robert J. | Director | A Award deriv | 2023-06-09 | 2023-06-12 | 60,000 | — | $0 | 60,000 | SEC↗ |
| MIDDLETON FRED A | Director | A Award deriv | 2023-06-09 | 2023-06-12 | 60,000 | — | $0 | 60,000 | SEC↗ |
| Multani Pratik S | Director | A Award deriv | 2023-06-09 | 2023-06-12 | 60,000 | — | $0 | 60,000 | SEC↗ |
| Andriole Michael T. | Chief Business Officer and C | P Buy | 2023-05-18 | 2023-05-19 | 51,700 | $1.14 | $58.9K | 357,015 | SEC↗ |
| Sherman Michael A. | Chief Executive Officer | P Buy | 2023-05-12 | 2023-05-16 | 75,015 | $1.12 | $84.0K | 87,000 | SEC↗ |
| Sherman Michael A. | Chief Executive Officer | P Buy | 2023-05-12 | 2023-05-16 | 11,985 | $1.13 | $13.5K | 11,985 | SEC↗ |
| DEMSKI MARTHA J | Director | P Buy | 2023-05-10 | 2023-05-11 | 18,000 | $1.11 | $20.0K | 72,055 | SEC↗ |
| Meyer Robert J. | Director | P Buy | 2023-05-08 | 2023-05-10 | 8,750 | $1.14 | $10.0K | 35,150 | SEC↗ |
| MIDDLETON FRED A | Director | P Buy | 2023-03-28 | 2023-03-29 | 20,000 | $1.21 | $24.2K | 60,000 | SEC↗ |
| Jakeman David | Principal Accounting Officer | S Sale | 2023-01-26 | 2023-01-26 | 3,230 | $1.76 | $5.7K | 136,752 | SEC↗ |
| Alrutz Michael Albert | Principal Executive Officer | A Award deriv | 2023-01-17 | 2023-01-19 | 128,550 | — | $0 | 128,550 | SEC↗ |
| Sherman Michael A. | Chief Executive Officer | A Award deriv | 2023-01-17 | 2023-01-19 | 557,050 | — | $0 | 557,050 | SEC↗ |
| Melemed Allen S. | Chief Medical Officer | A Award deriv | 2023-01-17 | 2023-01-19 | 154,260 | — | $0 | 154,260 | SEC↗ |
| Jakeman David | Principal Accounting Officer | A Award deriv | 2023-01-17 | 2023-01-19 | 24,950 | — | $0 | 24,950 | SEC↗ |
| Andriole Michael T. | Chief Business Officer and C | A Award deriv | 2023-01-17 | 2023-01-19 | 192,825 | — | $0 | 192,825 | SEC↗ |
| Alrutz Michael Albert | Principal Executive Officer | A Award | 2023-01-17 | 2023-01-19 | 21,450 | — | $0 | 142,015 | SEC↗ |
| Sherman Michael A. | Chief Executive Officer | A Award | 2023-01-17 | 2023-01-19 | 92,950 | — | $0 | 222,995 | SEC↗ |
| Melemed Allen S. | Chief Medical Officer | A Award | 2023-01-17 | 2023-01-19 | 25,740 | — | $0 | 47,887 | SEC↗ |
| Jakeman David | Principal Accounting Officer | A Award | 2023-01-17 | 2023-01-19 | 12,450 | — | $0 | 139,982 | SEC↗ |
| Andriole Michael T. | Chief Business Officer and C | A Award | 2023-01-17 | 2023-01-19 | 32,175 | — | $0 | 294,899 | SEC↗ |
| MIDDLETON FRED A | Director | P Buy | 2022-09-29 | 2022-10-03 | 20,000 | $1.86 | $37.2K | 40,000 | SEC↗ |
| Jakeman David | Principal Accounting Officer | S Sale | 2022-09-29 | 2022-09-30 | 4,400 | $1.86 | $8.2K | 127,532 | SEC↗ |
| Andriole Michael T. | Chief Business Officer and C | M Exercise deriv | 2022-08-25 | 2022-08-29 | 50,000 | — | $0 | 450,000 | SEC↗ |
| Andriole Michael T. | Chief Business Officer and C | M Exercise | 2022-08-25 | 2022-08-29 | 50,000 | $2.09 | $104.5K | 262,724 | SEC↗ |
| Sherman Michael A. | Chief Executive Officer | M Exercise deriv | 2022-07-25 | 2022-07-26 | 100,000 | — | $0 | 1,150,000 | SEC↗ |
| Sherman Michael A. | Chief Executive Officer | M Exercise deriv | 2022-07-25 | 2022-07-27 | 100,000 | — | $0 | 1,150,000 | SEC↗ |
| Sherman Michael A. | Chief Executive Officer | M Exercise | 2022-07-25 | 2022-07-26 | 100,000 | $2.09 | $209.0K | 125,364 | SEC↗ |
| Sherman Michael A. | Chief Executive Officer | M Exercise | 2022-07-25 | 2022-07-27 | 100,000 | $2.09 | $209.0K | 125,364 | SEC↗ |
| DEMSKI MARTHA J | Director | A Award deriv | 2022-06-23 | 2022-06-24 | 50,000 | — | $0 | 50,000 | SEC↗ |
| Gilliss Catherine | Director | A Award deriv | 2022-06-23 | 2022-06-24 | 50,000 | — | $0 | 50,000 | SEC↗ |
| Machado Patrick | Director | A Award deriv | 2022-06-23 | 2022-06-24 | 50,000 | — | $0 | 50,000 | SEC↗ |
| Meyer Robert J. | Director | A Award deriv | 2022-06-23 | 2022-06-24 | 50,000 | — | $0 | 50,000 | SEC↗ |
| MIDDLETON FRED A | Director | A Award deriv | 2022-06-23 | 2022-06-24 | 50,000 | — | $0 | 50,000 | SEC↗ |
| Multani Pratik S | Director | A Award deriv | 2022-06-23 | 2022-06-24 | 50,000 | — | $0 | 50,000 | SEC↗ |
| Vakiener Victoria | Director | A Award deriv | 2022-06-23 | 2022-06-24 | 50,000 | — | $0 | 50,000 | SEC↗ |
| Meyer Robert J. | Director | P Buy | 2022-05-19 | 2022-05-20 | 9,981 | $2.06 | $20.6K | 24,981 | SEC↗ |
| Meyer Robert J. | Director | P Buy | 2022-05-19 | 2022-05-20 | 1,419 | $2.05 | $2.9K | 26,400 | SEC↗ |
| MIDDLETON FRED A | Director | P Buy | 2022-05-19 | 2022-05-20 | 20,000 | $2.04 | $40.8K | 20,000 | SEC↗ |
| DEMSKI MARTHA J | Director | P Buy | 2022-05-17 | 2022-05-17 | 10,000 | $1.61 | $16.1K | 54,055 | SEC↗ |
| Andriole Michael T. | Chief Business Officer and C | P Buy | 2022-05-17 | 2022-05-18 | 15,000 | $1.71 | $25.6K | 212,724 | SEC↗ |
| Jakeman David | Principal Accounting Officer | S Sale | 2022-02-04 | 2022-02-04 | 3,300 | $5.56 | $18.3K | 117,666 | SEC↗ |
| Sherman Michael A. | Chief Executive Officer | A Award deriv | 2022-01-18 | 2022-01-20 | 875,000 | — | $0 | 875,000 | SEC↗ |
| Andriole Michael T. | Chief Business Officer and C | A Award deriv | 2022-01-18 | 2022-01-20 | 300,000 | — | $0 | 300,000 | SEC↗ |
| Melemed Allen S. | Chief Medical Officer | A Award deriv | 2022-01-18 | 2022-01-20 | 240,000 | — | $0 | 240,000 | SEC↗ |
| Jakeman David | Principal Accounting Officer | A Award deriv | 2022-01-18 | 2022-01-20 | 29,900 | — | $0 | 29,900 | SEC↗ |
| Jakeman David | Principal Accounting Officer | A Award | 2022-01-18 | 2022-01-20 | 14,900 | — | $0 | 120,966 | SEC↗ |
| Jakeman David | Principal Accounting Officer | S Sale | 2021-09-30 | 2021-09-30 | 4,590 | $6.19 | $28.4K | 106,066 | SEC↗ |
| CANTEX PHARMACEUTICALS, INC. | 10% Owner | S Sale | 2021-09-14 | 2021-09-16 | 6,500,000 | $5.75 | $37.38M | 3,500,000 | SEC↗ |
| MIDDLETON FRED A | Director | P Buy | 2021-06-28 | 2021-06-29 | 6,950 | $7.83 | $54.4K | 207,523 | SEC↗ |
| MIDDLETON FRED A | Director | P Buy | 2021-06-25 | 2021-06-29 | 3,050 | $7.78 | $23.7K | 200,573 | SEC↗ |
| Vakiener Victoria | Director | A Award deriv | 2021-06-23 | 2021-06-25 | 35,000 | — | $0 | 35,000 | SEC↗ |
| DEMSKI MARTHA J | Director | A Award deriv | 2021-06-23 | 2021-06-25 | 35,000 | — | $0 | 35,000 | SEC↗ |
| Gilliss Catherine | Director | A Award deriv | 2021-06-23 | 2021-06-25 | 35,000 | — | $0 | 35,000 | SEC↗ |
| Machado Patrick | Director | A Award deriv | 2021-06-23 | 2021-06-25 | 35,000 | — | $0 | 35,000 | SEC↗ |
| Meyer Robert J. | Director | A Award deriv | 2021-06-23 | 2021-06-25 | 35,000 | — | $0 | 35,000 | SEC↗ |
| MIDDLETON FRED A | Director | A Award deriv | 2021-06-23 | 2021-06-25 | 35,000 | — | $0 | 35,000 | SEC↗ |
| Multani Pratik S | Director | A Award deriv | 2021-06-23 | 2021-06-25 | 35,000 | — | $0 | 35,000 | SEC↗ |
| Vakiener Victoria | Director | A Award deriv | 2021-04-22 | 2021-04-26 | 60,000 | — | $0 | 60,000 | SEC↗ |
| Jakeman David | Principal Accounting Officer | M Exercise deriv | 2021-04-05 | 2021-04-07 | 5,250 | — | $0 | 0 | SEC↗ |
| Jakeman David | Principal Accounting Officer | S Sale | 2021-04-05 | 2021-04-07 | 1,284 | $9.68 | $12.4K | 102,705 | SEC↗ |
| Jakeman David | Principal Accounting Officer | M Exercise | 2021-04-05 | 2021-04-07 | 5,250 | $2.35 | $12.3K | 103,989 | SEC↗ |
| Meyer Robert J. | Director | P Buy | 2021-03-01 | 2021-03-01 | 1,500 | $9.80 | $14.7K | 15,000 | SEC↗ |
| Jakeman David | Principal Accounting Officer | S Sale | 2021-01-28 | 2021-01-29 | 3,211 | $8.61 | $27.6K | 96,906 | SEC↗ |
| Andriole Michael T. | Chief Business Officer and C | A Award deriv | 2021-01-22 | 2021-01-26 | 250,000 | — | $0 | 250,000 | SEC↗ |
| Jakeman David | Principal Accounting Officer | A Award deriv | 2021-01-22 | 2021-01-26 | 30,000 | — | $0 | 30,000 | SEC↗ |
| Chief Medical Officer | A Award deriv | 2021-01-22 | 2021-01-26 | 190,000 | — | $0 | 190,000 | SEC↗ | |
| Sherman Michael A. | Chief Executive Officer | A Award deriv | 2021-01-22 | 2021-01-26 | 700,000 | — | $0 | 700,000 | SEC↗ |
| Jakeman David | Principal Accounting Officer | A Award | 2021-01-22 | 2021-01-26 | 15,000 | — | $0 | 100,117 | SEC↗ |
| Jakeman David | Principal Accounting Officer | A Award deriv | 2020-12-21 | 2020-12-23 | 1,500 | — | $0 | 1,500 | SEC↗ |
| DEMSKI MARTHA J | Director | M Exercise deriv | 2020-11-17 | 2020-11-19 | 7,042 | — | $0 | 0 | SEC↗ |
| DEMSKI MARTHA J | Director | M Exercise | 2020-11-17 | 2020-11-19 | 7,042 | $2.35 | $16.5K | 7,042 | SEC↗ |
| DEMSKI MARTHA J | Director | G Gift | 2020-11-17 | 2020-11-19 | 7,042 | — | $0 | 0 | SEC↗ |
| DEMSKI MARTHA J | Director | G Gift | 2020-11-17 | 2020-11-19 | 7,042 | — | $0 | 44,055 | SEC↗ |
| Jakeman David | Principal Accounting Officer | S Sale | 2020-10-02 | 2020-10-02 | 4,270 | $2.48 | $10.6K | 85,117 | SEC↗ |
| Meyer Robert J. | Director | P Buy | 2020-08-19 | 2020-08-19 | 3,500 | $2.92 | $10.2K | 13,500 | SEC↗ |
| DEMSKI MARTHA J | Director | M Exercise deriv | 2020-08-10 | 2020-08-11 | 1,584 | — | $0 | 0 | SEC↗ |
| DEMSKI MARTHA J | Director | S Sale | 2020-08-10 | 2020-08-11 | 1,584 | $3.25 | $5.1K | 0 | SEC↗ |
| DEMSKI MARTHA J | Director | M Exercise | 2020-08-10 | 2020-08-11 | 1,584 | $3.16 | $5.0K | 1,584 | SEC↗ |
| DEMSKI MARTHA J | Director | M Exercise deriv | 2020-08-07 | 2020-08-10 | 2,500 | — | $0 | 1,584 | SEC↗ |
| DEMSKI MARTHA J | Director | M Exercise | 2020-08-07 | 2020-08-10 | 2,500 | $3.16 | $7.9K | 2,500 | SEC↗ |
| DEMSKI MARTHA J | Director | S Sale | 2020-08-07 | 2020-08-10 | 2,500 | $3.25 | $8.1K | 0 | SEC↗ |
| DEMSKI MARTHA J | Director | M Exercise deriv | 2020-08-06 | 2020-08-10 | 2,500 | — | $0 | 4,084 | SEC↗ |
| DEMSKI MARTHA J | Director | M Exercise | 2020-08-06 | 2020-08-10 | 2,500 | $3.16 | $7.9K | 2,500 | SEC↗ |
| DEMSKI MARTHA J | Director | S Sale | 2020-08-06 | 2020-08-10 | 2,500 | $3.29 | $8.2K | 0 | SEC↗ |
| DEMSKI MARTHA J | Director | M Exercise deriv | 2020-08-05 | 2020-08-06 | 2,500 | — | $0 | 6,584 | SEC↗ |
| DEMSKI MARTHA J | Director | M Exercise | 2020-08-05 | 2020-08-06 | 2,500 | $3.16 | $7.9K | 2,500 | SEC↗ |
| DEMSKI MARTHA J | Director | S Sale | 2020-08-05 | 2020-08-06 | 2,500 | $3.27 | $8.2K | 0 | SEC↗ |
| DEMSKI MARTHA J | Director | M Exercise deriv | 2020-08-04 | 2020-08-06 | 5,000 | — | $0 | 9,084 | SEC↗ |
| DEMSKI MARTHA J | Director | M Exercise | 2020-08-04 | 2020-08-06 | 5,000 | $3.16 | $15.8K | 5,000 | SEC↗ |
| DEMSKI MARTHA J | Director | S Sale | 2020-08-04 | 2020-08-06 | 5,000 | $3.25 | $16.3K | 0 | SEC↗ |
| Melemed Allen S. | Chief Medical Officer | A Award deriv | 2020-06-19 | 2020-06-23 | 400,000 | — | $0 | 400,000 | SEC↗ |
| DEMSKI MARTHA J | Director | A Award deriv | 2020-06-11 | 2020-06-15 | 35,000 | — | $0 | 35,000 | SEC↗ |
| Multani Pratik S | Director | A Award deriv | 2020-06-11 | 2020-06-15 | 35,000 | — | $0 | 35,000 | SEC↗ |
| MIDDLETON FRED A | Director | A Award deriv | 2020-06-11 | 2020-06-15 | 35,000 | — | $0 | 35,000 | SEC↗ |
| Meyer Robert J. | Director | A Award deriv | 2020-06-11 | 2020-06-15 | 35,000 | — | $0 | 35,000 | SEC↗ |
| Machado Patrick | Director | A Award deriv | 2020-06-11 | 2020-06-15 | 35,000 | — | $0 | 35,000 | SEC↗ |
| Greissing Ed | Director | A Award deriv | 2020-06-11 | 2020-06-15 | 35,000 | — | $0 | 35,000 | SEC↗ |
| Gilliss Catherine | Director | A Award deriv | 2020-06-11 | 2020-06-15 | 35,000 | — | $0 | 35,000 | SEC↗ |
| Andriole Michael T. | Chief Business Officer | P Buy | 2020-03-16 | 2020-03-17 | 33,300 | $1.43 | $47.6K | 149,729 | SEC↗ |
| MIDDLETON FRED A | Director | P Buy | 2020-03-12 | 2020-03-16 | 50,000 | $1.40 | $70.0K | 197,523 | SEC↗ |
| Sherman Michael A. | Chief Executive Officer | P Buy | 2020-03-12 | 2020-03-16 | 72,995 | $1.45 | $105.8K | 102,995 | SEC↗ |
| Multani Pratik S | Director | A Award deriv | 2020-02-21 | 2020-02-25 | 60,000 | — | $0 | 60,000 | SEC↗ |
| Nichols Garrett | Chief Medical Officer | S Sale | 2020-02-10 | 2020-02-11 | 8,805 | $1.68 | $14.8K | 260,066 | SEC↗ |
| Jakeman David | Principal Accounting Officer | S Sale | 2020-02-07 | 2020-02-11 | 2,290 | $1.70 | $3.9K | 87,876 | SEC↗ |
| Nichols Garrett | Chief Medical Officer | S Sale | 2020-02-07 | 2020-02-11 | 2,550 | $1.70 | $4.3K | 268,871 | SEC↗ |
| Jakeman David | Principal Accounting Officer | A Award deriv | 2020-01-21 | 2020-01-23 | 28,320 | — | $0 | 28,320 | SEC↗ |
| Nichols Garrett | Chief Medical Officer | A Award deriv | 2020-01-21 | 2020-01-23 | 192,500 | — | $0 | 192,500 | SEC↗ |
| Andriole Michael T. | Chief Business Officer | A Award deriv | 2020-01-21 | 2020-01-23 | 192,500 | — | $0 | 192,500 | SEC↗ |
| Sherman Michael A. | Chief Executive Officer | A Award deriv | 2020-01-21 | 2020-01-23 | 632,500 | — | $0 | 632,500 | SEC↗ |
| Jakeman David | Principal Accounting Officer | A Award | 2020-01-21 | 2020-01-23 | 14,160 | — | $0 | 90,166 | SEC↗ |
| Nichols Garrett | Chief Medical Officer | S Sale | 2020-01-07 | 2020-01-08 | 30,680 | $2.15 | $66.0K | 271,421 | SEC↗ |
| MIDDLETON FRED A | Director | P Buy | 2019-11-13 | 2019-11-13 | 30,000 | $1.82 | $54.6K | 147,523 | SEC↗ |
| MIDDLETON FRED A | Director | P Buy | 2019-11-11 | 2019-11-13 | 20,000 | $1.66 | $33.2K | 117,523 | SEC↗ |
| Meyer Robert J. | Director | P Buy | 2019-11-06 | 2019-11-06 | 10,000 | $1.58 | $15.8K | 10,000 | SEC↗ |
| Andriole Michael T. | Chief Business Officer | P Buy | 2019-11-06 | 2019-11-07 | 100,000 | $1.56 | $156.0K | 100,000 | SEC↗ |
| Jakeman David | Principal Accounting Officer | A Award | 2019-09-26 | 2019-09-30 | 56,000 | — | $0 | 76,006 | SEC↗ |
| Nichols Garrett | Chief Medical Officer | F Tax w/h | 2019-07-25 | 2019-07-26 | 7,625 | $3.49 | $26.6K | 300,056 | SEC↗ |
| Jakeman David | Principal Accounting Officer | A Award deriv | 2019-06-20 | 2019-06-24 | 10,000 | — | $0 | 10,000 | SEC↗ |
| Meyer Robert J. | Director | A Award deriv | 2019-06-20 | 2019-06-24 | 21,000 | — | $0 | 21,000 | SEC↗ |
| Renaud Ronald C JR | Director | A Award deriv | 2019-06-20 | 2019-06-24 | 21,000 | — | $0 | 21,000 | SEC↗ |
| MIDDLETON FRED A | Director | A Award deriv | 2019-06-20 | 2019-06-24 | 21,000 | — | $0 | 21,000 | SEC↗ |
| DEMSKI MARTHA J | Director | A Award deriv | 2019-06-20 | 2019-06-24 | 21,000 | — | $0 | 21,000 | SEC↗ |